<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142584</url>
  </required_header>
  <id_info>
    <org_study_id>NEB324</org_study_id>
    <nct_id>NCT00142584</nct_id>
  </id_info>
  <brief_title>Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension</brief_title>
  <official_title>An Open-Label, Randomized Study Evaluating the Long-Term Effects of Metoprolol Versus Nebivolol as Monotherapy or in Combination With Amlodipine or Hydrochlorothiazide for the Treatment of Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Bertek Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Bertek Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate long-term safety,tolerability and blood pressure
      effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be
      given alone or in combination with other drugs that are commonly used in the treatment of
      hypertension
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50 million Americans have hypertension defined as a systolic blood pressure
      (SBP) greater then or equal to 140 mmHg and/or a diastolic blood pressure (DBP) greater then
      or equal to 90 mmHg. To control blood pressure, more than 2 agents are required in many
      patients. The current study is a randomized, titration-to-effect, open-label, multi center
      study. Patients will be randomized to either nebivolol or metoprolol. The dose of the
      randomized treatment can be titrated as needed to achieve blood pressure control. If
      necessary, additional antihypertensive agents (calcium antagonist, diuretic, etc.) can be
      added to achieve control. Patients will be seen every 1-3 months for approximately 18 months
      to assess long-term safety, tolerability and effectiveness of nebivolol versus metoprolol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Anticipated">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average sitting DBP taken at trough at the end of treatment compared to baseline (baseline is defined as the baseline of the feeder study).</measure>
    <time_frame>During study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SBP, pulse pressure and heart rate at peak and trough drug effects measured in the supine, sitting and standing positions.</measure>
    <time_frame>During study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, ECGs, laboratory evaluations</measure>
    <time_frame>During study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1-NEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebivolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-MET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.</description>
    <arm_group_label>1-NEB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.</description>
    <arm_group_label>2-MET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of previous nebivolol study

          -  Stage 1-2 HTN at baseline of first study

        Exclusion Criteria:

          -  Recent myocardial infarction or stroke

          -  Contraindications to beta blocker therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Betty S Riggs, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mylan Pharmaceuticals Inc.</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>March 6, 2008</last_update_submitted>
  <last_update_submitted_qc>March 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andrea Miller, Vice President-Regulatory Affairs</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <keyword>safety and tolerability study</keyword>
  <keyword>hypertension</keyword>
  <keyword>beta-blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

